BYDUREON BCise Injectable medicine now available in the US for type-2 diabetes patients

The new formulation is proven to reduce blood sugar levels and may have the added benefit of weight loss.

AstraZeneca has announced that BYDUREON BCise (exenatide extended-release) injectable suspension 2 mg is now available in pharmacies across the US. BYDUREON BCise was recently approved by the FDA for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to diet and exercise, to improve glycemic control.

BYDUREON BCise Injectable medicine now available in the US for type-2 diabetes patients

BYDUREON BCise is a new formulation of BYDUREON (exenatide extended-release) injectable suspension 2 mg in an improved once-weekly, single-dose autoinjector device. It is designed for patient ease and convenience in a pre-filled device with a pre-attached hidden needle. The new formulation of BYDUREON BCise is proven to reduce blood sugar levels and may have the added benefit of weight loss, although not a weight loss medicine. The medication is administered in three simple steps – mix, unlock, inject.

Rod Wooten, Vice President, Cardiovascular and Metabolic Diseases, AstraZeneca, said: "We're pleased that BYDUREON BCise is now available for adults with type 2 diabetes. This new formulation helps to provide consistent glycemic control, in addition to the powerful HbA1c reductions and added benefit of weight loss, now in a simply improved device."

Across two clinical trials, average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds were achieved when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks. The most common adverse reactions reported in ≥5% of patients in clinical trials were nausea (8.2%) and adverse events associated with injection-site nodules (10.5%).

Virginia Valentine APRN, BC-ADM, CDE, FAADE, said: "Managing type 2 diabetes is complicated and requires daily attention to meal planning, exercise and medications. A once-weekly prescription option in an easy-to-use device, like BYDUREON BCise, can help simplify a patient's regimen and help them achieve diabetes control goals."

Read More


Categories

Market News

Other news in “Market News”

New automated VPT systems for topical drug performance testing

New automated VPT systems for topical drug performance testing 

11 Jan 2018
3D human sebaceous glands technology for skin care applications

3D human sebaceous glands technology for skin care applications 

9 Jan 2018
Tjoapack investment triples its bottling capacity

Tjoapack investment triples its bottling capacity 

8 Jan 2018